BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 16111748)

  • 1. Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved hematological remission after different therapeutic procedures.
    Chávez-González A; Ayala-Sánchez M; Sánchez-Valle E; Ruiz-Sánchez E; Arana-Trejo RM; Vela-Ojeda J; Mayani H
    Leuk Res; 2006 Mar; 30(3):286-95. PubMed ID: 16111748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe functional alterations in vitro in CD34(+) cell subpopulations from patients with chronic myeloid leukemia.
    Chávez-González A; Rosas-Cabral A; Vela-Ojeda J; González JC; Mayani H
    Leuk Res; 2004 Jun; 28(6):639-47. PubMed ID: 15120942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
    Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF
    Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eilatin: a novel marine alkaloid inhibits in vitro proliferation of progenitor cells in chronic myeloid leukemia patients.
    Einat M; Lishner M; Amiel A; Nagler A; Yarkorli S; Rudi A; Kashman Y; Markel D; Fabian I
    Exp Hematol; 1995 Dec; 23(14):1439-44. PubMed ID: 8542929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate.
    Perseghin P; Gambacorti-Passerini C; Tornaghi L; Dassi M; Pioltelli P; Parma M; Colnaghi F; Giudici G; Elli E; Fumagalli M; Ponchio L; Biondi A; Pogliani EM
    Transfusion; 2005 Jul; 45(7):1214-20. PubMed ID: 15987369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
    Simon W; Segel GB; Lichtman MA
    Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
    Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
    Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-selectin expression is low on CD34+ cells from patients with chronic myeloid leukemia and interferon-a up-regulates this expression.
    Martín-Henao GA; Quiroga R; Sureda A; González JR; Moreno V; García J
    Haematologica; 2000 Feb; 85(2):139-46. PubMed ID: 10681720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effect of type I interferons on hematopoietic progenitor cells: failure of interferons to inhibit IL-3-stimulated normal and CML myeloid progenitors.
    Després D; Goldschmitt J; Aulitzky WE; Huber C; Peschel C
    Exp Hematol; 1995 Dec; 23(14):1431-8. PubMed ID: 8542928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
    Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
    Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
    Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
    Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
    Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K
    Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent antileukemic activity of the novel agents norsegoline and dibezine.
    Einat M; Nagler A; Lishner M; Amiel A; Yarkoni S; Rudi A; Gellerman G; Kashman Y; Fabian I
    Clin Cancer Res; 1995 Aug; 1(8):823-9. PubMed ID: 9816051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients.
    Ramanarayanan J; Dunford LM; Baer MR; Sait SN; Lawrence W; McCarthy PL
    Leuk Res; 2006 Jun; 30(6):701-5. PubMed ID: 16330096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells.
    Agis H; Jaeger E; Doninger B; Sillaber C; Marosi C; Drach J; Schwarzinger I; Valent P; Oehler L
    Eur J Clin Invest; 2006 Jun; 36(6):402-8. PubMed ID: 16684124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and selection of benign stem cells in chronic myeloid leukemia.
    Lemoli RM
    Haematologica; 1993; 78(6):393-400. PubMed ID: 8175034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment.
    Holtz M; Forman SJ; Bhatia R
    Cancer Res; 2007 Feb; 67(3):1113-20. PubMed ID: 17283145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro functional alterations in the hematopoietic system of adult patients with acute lymphoblastic leukemia.
    Martínez-Jaramillo G; Vela-Ojeda J; Sánchez-Valle E; Montesinos JJ; Mayani H
    Leuk Res; 2007 Jan; 31(1):83-9. PubMed ID: 16769114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.
    Savani BN; Montero A; Kurlander R; Childs R; Hensel N; Barrett AJ
    Bone Marrow Transplant; 2005 Dec; 36(11):1009-15. PubMed ID: 16205732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy of chronic myelogenous leukemia in 2004].
    Hochhaus A; Berger U; Hehlmann R
    Dtsch Med Wochenschr; 2004 Oct; 129(40):2122-7. PubMed ID: 15455305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.